Literature DB >> 3486696

Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells.

S K Jacobs, G Melin, B Holcomb, C W Parham, P L Kornblith, E A Grimm.   

Abstract

The killing of Fischer rat 9L glioma in vitro by lymphokine-activated killer (LAK) cells was studied. LAK cells generated by culturing Fischer spleen cells with recombinant interleukin 2 markedly lysed glioma cells but did not kill syngeneic normal brain tissue in a chromium release microcytotoxicity assay. Susceptibility of glioma to lysis by LAK cells was markedly diminished by pretreating the glioma cells with trypsin or chymotrypsin but was unaffected by pretreatment with neuraminidase, glycosidases, or sodium periodate. These results suggest that LAK cell killing of glioma is probably tumor-selective and that a crucial cell surface determinant on glioma cells responsible for its tumor-selective lysis by LAK is a protein sensitive to trypsin and chymotrypsin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486696     DOI: 10.1016/0006-8993(86)91150-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.

Authors:  H Matsuura; H Imaya
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

3.  Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2.

Authors:  H Imaya; H Matsuura; M Kudo; S Nakazawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.

Authors:  S J Tapscott; A D Miller; J M Olson; M S Berger; M Groudine; A M Spence
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

5.  Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.

Authors:  Seok-Gu Kang; Chung Hun Ryu; Sin Soo Jeun; Chun Kun Park; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2004-02-13       Impact factor: 1.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.